RBM17 Promotes the Chemoresistance of Oral Squamous Cancer Cells Through Checkpoint Kinase 1
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073127 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Miyuka Nakahara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Mouth Neoplasms, RNA-Binding Proteins, Checkpoint Kinase 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oral squamous cell carcinoma (OSCC) is one of the most common types of cancer in the head and neck region. In advanced stages of OSCC, chemotherapy is commonly used for treatment, despite some cancer cells having low sensitivity to anticancer drugs. We focused on RBM17/SPF45 as an essential drug-sensitizing factor in the context of malignant cells acquiring chemoresistance. Here, we demonstrate how RBM17 affects anticancer drug resistance in OSCC and we suggest the possible mechanism underlying its effects. After exposing oral cancer cell lines to fluorouracil (5-FU) and cisplatin, but not paclitaxel, the gene and protein expression of RBM17 increased. We found that siRNA-mediated RBM17-knockdown of the cell lines gained a significantly higher sensitivity to 5-FU, which was remarkably followed by a decrease in the expression of checkpoint kinase 1 (CHEK1) protein, whereas treatment with a CHEK1 inhibitor did not affect RBM17 protein expression in the oral cancer cell lines. These results indicate that RBM17 is a factor involved in the development of resistance to cytotoxic chemotherapy. We propose the underlying mechanism that RBM17 promotes CHEK1 protein expression in the ATM/ATR pathway, triggering the development of chemoresistance in cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
- Department of Oral and Maxillofacial Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
- Oncology Innovation Center, Fujita Health University, Toyoake 470-1192, Japan.
- xFOREST Therapuetics, Co., Ltd., Kyoto 602-0841, Japan.
- Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
ORCID-Profile: Ryosuke Arai, Isao Tokuoka, Kazuhiro Fukumura, Akila Mayeda, Masakazu Yashiro
Zitieren
APA
Nakahara, M., Arai, R., Tokuoka, I., Fukumura, K., Mayeda, A., Yashiro, M., & Nakahara, H. (2025). RBM17 Promotes the Chemoresistance of Oral Squamous Cancer Cells Through Checkpoint Kinase 1. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073127
Vancouver
Nakahara M, Arai R, Tokuoka I, Fukumura K, Mayeda A, Yashiro M, et al. RBM17 Promotes the Chemoresistance of Oral Squamous Cancer Cells Through Checkpoint Kinase 1. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073127
BibTeX
@article{Nakahara2025,
author = {Nakahara, Miyuka and Arai, Ryosuke and Tokuoka, Isao and Fukumura, Kazuhiro and Mayeda, Akila and Yashiro, Masakazu and Nakahara, Hirokazu},
title = {RBM17 Promotes the Chemoresistance of Oral Squamous Cancer Cells Through Checkpoint Kinase 1},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073127}
}
EUVIMED